Background: Type-II MI is defined as myocardial infarction (MI) secondary to ischemia due to either increased oxygen demand or decreased supply. This categorization has been used for the last five years, yet, little is known about patient characteristics and clinical outcomes. In the current work we assessed the epidemiology, causes, management and outcomes of type II MI patients.
Introduction
In 2007, a joint Task Force of the American College of Cardiology, American Heart Association, European Society of Cardiology and the World Heart Federation published a redefinition of myocardial infarction (MI). [1] Type-II MI was defined as MI secondary to ischemia due to either increased oxygen demand or decreased supply caused by conditions as coronary artery spasm, coronary embolism, anemia, arrhythmias, hypertension, or hypotension. [1] In many of these clinical situations, including sepsis and post-operative state, cardiac troponin is frequently elevated. [2] [3] [4] [5] The underlying mechanism for this troponin elevation is multifactorial and often indicates myocardial necrosis rather than myocardial ischemia. [3] The incidence of type-II MI among all patients is currently unknown and a rate of 4% was reported among patients who experienced recurrent MI [6] [7] [8] . However, patient characteristics, clinical presentation, underlying contributing factors, management and outcomes, have not been elucidated.
The Acute Coronary Syndrome Israeli Survey (ACSIS) is a prospective nation-wide consecutive collection of data of acute coronary syndrome patients in Israel. The survey is conducted biennially over a 2-month period and data on all acute coronary syndrome patients in 26 public hospitals in Israel are provided by each participating center by means of the prespecified case report forms. The Israel Heart Society is responsible for the collection of all case report forms and for maintaining the survey database. [9] Since 2008, the survey has implemented the universal definition of MI. Accordingly, we have performed a comparative analysis between patients with type-I and type-II MI who were enrolled in two consecutive national ACSIS.
Patients and Methods

Patient Population
During the 2-month period in 2008 and 2010, detailed data was collected in all 26 ICCU and cardiology wards in all public hospitals in Israel, on patients admitted with the diagnosis of ACS. In addition, data from a representative sample of 37 Internal Medicine wards was collected by the Israel Society of Internal Medicine.
The study population consisted of 2,818 patients with myocardial infraction, of which 2,691 experienced type-I and 127 experienced type-II MI, who were included in the ACSIS registry in 2008 and 2010. Complications of coronary angiography and intervention were documented only in ACSIS 2010.
In-hospital and 30-day outcomes were available for all patients. Mortality at one-year follow-up was available for 93% of the patients. Demographic, historical and clinical data, admission ECG parameters, presence of Q-waves at discharge, medical therapies in-hospital and at discharge, invasive procedures, inhospital complications and follow-up data were recorded on predefined forms by dedicated physicians. Patients' functional level was categorized as: normal, mildly impaired or significantly impaired. The existence of anemia was defined at the discretion of the treating physician, based on normal laboratory range in each participating medical center.
Diagnosis and Definitions of Myocardial Infarction
The diagnosis of type-I and type-II MI were at the discretion of the treating physician, according to the 2 nd universal definition of MI. [1] To assure compliance with this definition a retrospective validation of the diagnosis of all type-II MI was performed, independently, by two expert physicians. [1] Patients for whom a specific valid cause for the type-II MI was not established were reclassified as type-I MI. Global Registry of Acute Coronary Events (GRACE) risk score was calculated for each admitted patient [10, 11] .
Ethics Statement
This register-based analysis of pre-existing data was conducted according to the principles expressed in the Declaration of Helsinki. The ACSIS was approved by all the ethical committees in each of the participating medical centers (File S1). Informed consent was specifically waived by the ethical committees of all participating medical centers.
Statistical Analysis
Statistical analysis was performed using SAS statistical software (version 8.2, SAS Institute, Cary, NC). Categorical variables were expressed as percentage, and continuous variables were expressed as mean 6 SD. Comparisons of variables were performed by ChiSquare and Fisher's exact test for categorical variables and by unpaired t-test test for continuous variables. All tests were twosided and p value,0.05 was considered statistically significant.
Results
Patient Characteristics and Clinical Presentation
Type-II MI was diagnosed in 178 of 2818 patients, of whom, 51 were re-classified as type-I MI because a specific valid cause for the type-II MI was not established. The final cohort of type II MI comprised 127 (4.5%) patients. Compared with type-I, patients with type-II MI were older by an average of 11.5 years and the percentage of females was 2-fold higher (Table 1) . Patients with type-II MI more often have a history of coronary revascularization, cardiovascular related comorbidities, and substantially higher rates of chronic renal failure and reduced functionality level (Table 1) . GRACE risk score was substantially higher among type II MI patients (150632 vs. 110635, p,0.0001), reflecting higher scores both among patients with STEMI (133634 vs. 96631, p,0.0001) and NSTEMI (154630 vs. 123635, p,0.0001). Clinical presentation varied between the two patient cohorts and patients with type-II were presented more often with atypical symptoms including dyspnea and arrhythmia, diagnosed more often with non-ST elevation MI and were more frequently admitted to an internal medicine ward and less to a cardiology department ( Table 2) . Table 3 specifies the main causes for type-II MI. Twenty six percent of the patients had more than one cause ( Table 3 ). The main causes were anemia, followed by sepsis, arrhythmia and postoperation. Sepsis as a cause of type-II MI was more common among patients presenting with STEMI compared with those presenting with NSTEMI (40.7% vs. 19.2%, p = 0.02). Other causes did not differ between STEMI and NSTEMI patients. In-hospital Management
Causes of Type II MI
Utilization of revascularization varied between groups (Table 4 ). Type-II MI patients were less often referred for primary and nonprimary angiography and of those who underwent coronary angiography, 50% had undergone PCI. In both groups, the utilization of an invasive strategy showed an inverse relationship to patient's risk, as assessed by GRACE risk score (Table 5) .
Patients with type-II MI had more complications during PCI. Specifically, they had undergone more cardio-pulmonary resuscitations and were referred more frequently for urgent CABG. Interestingly, there were no differences in the culprit vessel between MI types (Table 4 ).
In and Out of Hospital Outcomes
Patients with type-II MI had higher rates of in-hospital complications including post-MI angina and heart failure ( Figure 1 ) and extended hospitalizations (7.566.3 vs. 665.3 days, p = 0.002). In-hospital and 30-day mortality rates were almost three times higher among patients with type-II compared to type-I MI (11.8% vs. 4.2%, p = 0.0005 and 13.6% vs. 4.9%, p = 0.0005, respectively). Thirty-day major adverse cardiac event rates defined as a composite of death, re-MI, CVA or urgent revascularization, were also significantly higher among patients with type-II MI (18.9% vs. 8.8%, p = 0.0001). Kaplan-Meier survival analysis shows significant differences between groups with overall reduced one-year survival rates among patients with type-II MI (76.1% vs. 91.4%, p,0.0001) (Figure 2 ). Out-of-hospital to one-year mortality rates were also higher among patients who experienced type-II compared to type I MI (4.4% vs. 12.2%. p,0.0001). Interestingly, patients with type-II MI who had two or more identifiable causes of their MI, compared to those with a single cause, had substantially higher 30-day mortality (30.4% vs. 9.8%, p = 0.009).
Patients with type-II MI less often received guideline-directed medical therapy. These differences were mostly distinctive for clopidogrel but were also significant for four other groups of medications, such as: aspirin, beta-blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers and HMGCoA reductase inhibitors (Table 6 ).
Discussion
The current national prospective survey analysis of close to 3000 patients with MI, demonstrates a near three-fold increase in short-and intermediate-term mortality among patients with type-II compared with type-I MI. This study, the first to characterize patients with type-II MI, shows that these patients, compared to type-I MI, are: 1) older and more frequently female, 2) have higher rates of multiple cardiac and non-cardiac comorbidities with a significantly higher GRACE risk score, 3) more frequently presented with atypical symptoms and diagnosed with NSTEMI, and 4) less frequently referred to coronary interventions and received fewer guideline-directed medications. In our cohort, type-II MI was diagnosed in 4.5% of all AMI patients and constituted 7% among patients admitted with NSTEMI. These data are in concordance with previous studies assessing the frequency of type II MI in selected populations with previous MI. [6, 7, 12, 13] Nevertheless, following implementation of the 3 rd universal definition of MI along with utilization of highsensitive troponin assays, it is quite possible the population of patients with type-II MI and specially type II NSTEMI will increase [14, 15] .
We observed substantial differences in baseline characteristics between patients admitted with type-II compared to type-I MI. Notably, patients with type-II MI are considerably older, more often women, they more frequently have a history of coronary revascularization, chronic renal failure, diabetes and lower functional status. Risk factors for type-II MI in specific clinical situations such as post-operative have been reported and comprised several variables including increased age, dependent functional status and renal failure. [16] It is conceivable, that elderly patients with multiple comorbidities and an underlying coronary disease would be more susceptible to clinical changes that may interfere with the delicate balance of myocardial supply and demand, ensuing in type-II MI.
Therapeutic strategy in the current study was at the discretion of the local medical team. Anemia and sepsis were identified as causes for MI in over 50% of the patients. These clinical conditions, along with frequent presence of chronic renal failure and significantly impaired functional capacity on one hand and the high cardiovascular risk score on the other imposed a great therapeutic decision-making challenge. Hence, additional data are needed in order to draw specific recommendations tailored to the various clinical conditions associated with type II MI. Considering the high cardiovascular risk score of patients with type II MI, recognition of subsets of cohorts, such as those experiencing postoperative MI, may allow to implement invasive strategy [2, 11, [17] [18] [19] . On the other hand, many of these patients may require initial stabilization of the cause of the MI. This obligatory time lag may dictate conservative approach with utilization of delayed invasive strategy only in selective patients. [20] Whether, in selected patient populations, a more invasive approach would benefit patients with type II MI has not been studied. Similarly, whether current recommended medical treatments would advantage patients with type II MI is at present unknown. Considering the complexity of this cohort, a potential important implication of our study is the need for dedicated studies to assess comprehensive therapeutic strategies in this growing patient population.
Short-term and intermediate outcomes differ between patients with type-II and type-I MI. In-hospital complications were substantially more frequent and short-term and intermediate mortality rates were near three-fold higher, reaching 13.6% and 23.9% at 30 days and 1-year, respectively. Similar 30-day mortality rates were previously noted in patients with perioperative MI. [2] Thus, our data further extends the relatively high mortality rates to a broader type-II patient population.
Limitations
The current study carries several limitations. In this national survey, patients admitted to non-cardiac intensive care units were not included. Thus, both the true frequency of type-II MI and the observed mortality rates, which are usually substantial among medical intensive-care patients, may be higher. Invasive strategy was at the discretion of the treating physicians and overall, only a minority of type-II MI patients were referred to coronary angiography. Specific reasons for such decisions were not gathered and accordingly, no recommendation regarding patient selection can be made. The relatively small number of type-II MI patients 
Conclusions
Type-II MI is not infrequent, especially among patients with NSTEMI. Compared to type-I MI, it is more frequent among the elderly with multiple comorbidities, high ACS risk score and associated with increased short and intermediate-term mortality. The implementation of current ACS guidelines to patients with type-II MI is challenging and more evidence-based patienttailored therapeutic strategies are warranted.
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